Tempus has expanded its AI-based Care Pathway Intelligence platform to cover breast cancer, following its acquisition of experience in lung, pancreatic, and ovarian cancers. The move is intended to enable oncologists to make more informed decisions about treatment through a determination of where patients might be helped by changing care pathways using real-world evidence.
Health Technology Insights: Klick Group Eyes Strong Future With Growth Investment
The company’s platform, which examines structured and unstructured clinical information, identifies patients who are not adhering to guideline-based treatment regimens. With the expansion into breast cancer, Tempus is looking to assist providers in providing more personalized and evidence-based care to more patients.
“Breast cancer is one of the most common cancers globally, and by expanding our platform, we hope to give providers the tools they need to improve outcomes,” said Dr. Kimberly Blackwell, Chief Medical Officer at Tempus. “This enhancement underscores our mission to use technology and data to close gaps in cancer care.”
Health Technology Insights: Game-Changing HSA Reforms Just Passed—Here’s What It Means for Healthcare
The Care Pathway Intelligence platform works by flagging deviations from clinical guidelines, surfacing insights that allow care teams to intervene earlier or adjust therapies as needed. It is built to integrate into existing clinical workflows and is supported by Tempus’ broader suite of genomic and clinical tools.
As part of this expansion, Tempus will work closely with oncology providers to implement the breast cancer module and collect feedback to continue improving the technology. The company believes this move will help standardize care and reduce variations in treatment practices.
With breast cancer affecting millions of patients worldwide, the platform’s new capabilities are expected to play a significant role in enhancing care delivery and supporting more consistent patient outcomes.
Health Technology Insights: Lives on the Line: Komen Speaks Out Against Reconciliation Bill as Millions Stand to Lose Coverage
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
